Program Overview
This CME/CE program will highlight optimal guideline directed medical therapy for patients with heart failure (HF). The expert faculty will first review current ACC/AHA and ESC recommendations for directed medical therapy to treat patients with heart failure with reduced ejection fraction (HFrEF). Following, the faculty will analyze clinical trial data for SGLT2is, vericiguat, and omecamtiv mecarbil therapeutics. Next, clinical strategies to manage adverse event symptoms and optimize adherence to treatment for HF patients will be discussed. The faculty will conclude with an interactive expert panel discussion, delving further into guideline directed medical therapy to treat and manage patients with heart failure.
Learning Objectives
- Review current recommendations (ACC/AHA and ESC) for guideline directed medical therapy for patients with HFrEF
- Highlight recent clinical trials demonstrating clinical benefit (reducing mortality and hospitalizations) with SGLT2is, vericiguat, and omecamtiv mecarbil
- Review best practice to optimize the interprofessional team approach
- Discuss common reasons for medical therapy intolerance and monitoring strategies to maximize tolerance and minimize adverse events (symptomatic hypotension, hyperkalemia, renal dysfunction, etc.)
Agenda
I. Current ACC/AHA and ESC Recommendations for Directed Medical Therapy to Treat Patients with HFrEF – Gregg Fonarow, MD
II. Clinical Trial Review for SGLT2is, Vericiguat, and Omecamtiv Mecarbil Therapeutics to Improve Outcomes in Patients with Heart Failure – Douglas Jennings, PharmD
III. Clinical Strategies to Manage Adverse Event Symptoms and Optimize Adherence to Treatment for HF Patients – Craig Beavers, PharmD
IV. Panel Discussion – Beth Davidson, DNP, ACNP, CCRN, CHFN, FHFSA & Faculty
Faculty
Beth Davidson, DNP, ACNP, CCRN, CHFN, FHFSA
Director, Heart Failure Disease Management Program
HCA TriStar Centennial Medical Center
Nashville, TN
Craig J. Beavers, PharmD
Cardiovascular Clinical Pharmacist
Adjunct Assistant Professor
University of Kentucky College of Pharmacy
Lexington, KY
Gregg C. Fonarow, MD
Eliot Corday Professor of Cardiovascular Medicine and Science
Director, Ahmanson-UCLA Cardiomyopathy Center
Co-director, UCLA Preventative Cardiology Program
Chief (Interim), UCLA Division of Cardiology
University of California, Los Angeles
Los Angeles, CA
Douglas Jennings, PharmD
Associate Professor of Pharmacy Practice
Clinical Pharmacist, Heart Transplant and MCS
New York Presbyterian Columbia University Medical Center
New York, NY
Disclosures of Relevant Financial Relationships
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships relating to the topics of this educational activity. Any relevant financial relationships are mitigated via a content review by planning committee members and faculty with no relevant financial relationships.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
| Faculty | Relationship Identified With: |
| Beth Davidson, DNP, ACNP, CCRN, CHFN, FHFSA | Consultant/Advisor: Abiomed
Speaker’s Bureau: Abbott; CMP Pharma |
| Craig J. Beavers, PharmD | Nothing to disclose |
| Gregg C. Fonarow, MD | Consultant/Advisor: Abbott; Amgen Inc.; AstraZeneca Pharmaceuticals; Bayer; Cytokinetics; Janssen Global Services, LLC; Medtronic; Merck & Co., Inc.; Novartis |
| Douglas Jennings, PharmD | Consultant/Advisor: Abiomed; La Jolla Pharmaceuticals; Novartis
Speaker’s Bureau: Abiomed; Merck & Co., Inc. |
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole McMenamin; Chelsey Benedek and Emma Boring hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this activity for a maximum of 1.0 AMA PRA Category 1 CreditTM.
AcademicCME designates this activity for a maximum of 1.0 CNE Contact Hour (Provider #P0491).
AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEUs) of continuing pharmacy education credit (UAN # JA4008190-0000-22-004-H04-P).
Clinicians should claim only credit commensurate with the extent of their participation in the activity.
Financial Support
This activity has been supported by an educational grant from Abiomed.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Abiomed do not recommend the use of any agent outside of the labeled indications.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 80% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].
